Ascendis Pharma A/S (NASDAQ:ASND) Q3 2023 Earnings Call Transcript

This is in the older children. When we go to the newborn we started now, we go for much more hardcore facts how to, for example benefit in sphinosis. Do we see the same element of fast fusion of the [indiscernible] or other things like that. And I think this is where we take a different age group finding out what can we really do that and that is what we are analyzing and building into our pivotal Phase III trial. So we are quite sure when we have the unblinding on that, we basically have already the element of discussion with regulatory agencies how we basically can iterate that.

Leland Gershell: And then one further question, if I may. As we look forward to the update from the one year follow-up from accomplish open label extension. Just wondering, would you be able to provide the retention rate in terms of patients who persisted in the OLE?

Jan Mikkelsen: At the one the data we will have to have all 47 patients.

Scott Smith: 57.

Jan Mikkelsen: 57 patients.

Operator: This does conclude today’s Ascendis Pharma third quarter earnings call. You may disconnect your lines at any time and have a wonderful day.